ClinicalTrials.gov

History of Changes for Study: NCT04101357
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
Latest version (submitted September 21, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 September 23, 2019 None (earliest Version on record)
2 November 14, 2019 Study Status
3 July 24, 2020 Recruitment Status, Contacts/Locations, Study Status, Study Identification, Eligibility and Oversight
4 January 20, 2021 Sponsor/Collaborators, Study Status, Study Identification, Eligibility, Outcome Measures and Study Description
5 March 11, 2021 Contacts/Locations and Study Status
6 July 22, 2021 Study Status and Contacts/Locations
7 April 28, 2022 Contacts/Locations, Study Status and IPDSharing
8 May 25, 2022 Study Status
9 August 11, 2022 Study Status
10 September 21, 2022 Contacts/Locations and Study Status
Comparison Format:

Scroll up to access the controls

Changes (Side-by-Side) for Study: NCT04101357
May 25, 2022 (v8) -- August 11, 2022 (v9)

Changes in: Study Status

Open or close this module Study Identification
Unique Protocol ID: BNT411-01 BNT411-01
Brief Title: Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
Official Title: Phase 1/2a, First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT411 as a Monotherapy in Patients With Solid Tumors and in Combination With Atezolizumab, Carboplatin and Etoposide in Patients With Chemotherapy-naïve Extensive-stage Small Cell Lung Cancer (ES-SCLC) Phase 1/2a, First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT411 as a Monotherapy in Patients With Solid Tumors and in Combination With Atezolizumab, Carboplatin and Etoposide in Patients With Chemotherapy-naïve Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Secondary IDs: 2019-003593-17 [EudraCT Number]2019-003593-17 [EudraCT Number]
Open or close this module Study Status
Record Verification: May 2022 August 2022
Overall Status: RecruitingRecruiting
Study Start: June 19, 2020 June 19, 2020
Primary Completion: July 2022 [Anticipated] July 2023 [Anticipated]
Study Completion: February 2024 [Anticipated] February 2024 [Anticipated]
First Submitted: September 20, 2019 September 20, 2019
First Submitted that
Met QC Criteria:
September 23, 2019 September 23, 2019
First Posted: September 24, 2019 [Actual] September 24, 2019 [Actual]
Last Update Submitted that
Met QC Criteria:
May 25, 2022 August 11, 2022
Last Update Posted: May 26, 2022 [Actual] August 12, 2022 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: BioNTech SE BioNTech SE
Responsible Party: Sponsor Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: YesYes
U.S. FDA-regulated Device: NoNo
Data Monitoring:
Open or close this module Study Description
Brief Summary: This first-in-human (FIH) trial aims to establish a safe dose of BNT411 as a monotherapy and in combination with atezolizumab, carboplatin and etoposide. BNT411 is a toll-like receptor 7 (TLR7) agonist which is expected to mount broad innate and adaptive immune reactions, especially in combination with cytotoxic therapies and immune checkpoint inhibitors. This first-in-human (FIH) trial aims to establish a safe dose of BNT411 as a monotherapy and in combination with atezolizumab, carboplatin and etoposide. BNT411 is a toll-like receptor 7 (TLR7) agonist which is expected to mount broad innate and adaptive immune reactions, especially in combination with cytotoxic therapies and immune checkpoint inhibitors.
Detailed Description:
Open or close this module Conditions
Conditions: Solid Tumor
Extensive-stage Small Cell Lung Cancer
Solid Tumor
Extensive-stage Small Cell Lung Cancer
Keywords: Solid Tumor
Extensive-stage Small Cell Lung Cancer
Solid Tumor
Extensive-stage Small Cell Lung Cancer
Open or close this module Study Design
Study Type: InterventionalInterventional
Primary Purpose: TreatmentTreatment
Study Phase: Phase 1/Phase 2Phase 1/Phase 2
Interventional Study Model: Sequential Assignment Sequential Assignment
Number of Arms: 33
Masking: None (Open Label)None (Open Label)
Allocation: Non-RandomizedNon-Randomized
Enrollment: 60 [Anticipated] 60 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Part 1A - monotherapy dose escalation
BNT411 monotherapy
Drug: BNT411
intravenous
Experimental: Part 1B combination dose escalation
BNT411 in combination with atezolizumab, carboplatin and etoposide
Drug: BNT411
intravenous
Drug: Atezolizumab
intravenous
Drug: Carboplatin
intravenous
Drug: Etoposide
intravenous
Experimental: Part 2 expansion cohorts
BNT411 either as monotherapy or in combination with other anti-cancer agents
Drug: BNT411
intravenous
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Incidence of DLTs
[ Time Frame: 21 Days ]

Occurrence of DLTs within a patient during the DLT evaluation period
Incidence of DLTs
[ Time Frame: 21 Days ]

Occurrence of DLTs within a patient during the DLT evaluation period
2. Incidence of TEAEs
[ Time Frame: up to 2 Years ]

Occurrence of treatment-emergent adverse events (TEAE) within a patient
Incidence of TEAEs
[ Time Frame: up to 2 Years ]

Occurrence of treatment-emergent adverse events (TEAE) within a patient
3. Incidence of IMP dose reductions
[ Time Frame: up to 2 Years ]

Occurrence of dose reduction of IMP within a patient due to treatment-emergent adverse events (TEAE)
Incidence of IMP dose reductions
[ Time Frame: up to 2 Years ]

Occurrence of dose reduction of IMP within a patient due to treatment-emergent adverse events (TEAE)
4. Incidence of IMP treatment discontinuations due to toxicity
[ Time Frame: up to 2 Years ]

Occurrence of discontinuation of IMP within a patient due to treatment-emergent adverse events (TEAE)
Incidence of IMP treatment discontinuations due to toxicity
[ Time Frame: up to 2 Years ]

Occurrence of discontinuation of IMP within a patient due to treatment-emergent adverse events (TEAE)
Secondary Outcome Measures:
1. Maximum Plasma Concentration (Cmax) of PK assessments
[ Time Frame: up to 2 Years ]

Maximum Plasma Concentration (Cmax) of PK assessments
[ Time Frame: up to 2 Years ]

2. Area under the curve (AUC) of PK assessments
[ Time Frame: up to 2 Years ]

Area under the curve (AUC) of PK assessments
[ Time Frame: up to 2 Years ]

3. Objective Response Rate (ORR)
[ Time Frame: up to 2 Years ]

ORR defined as the proportion of patients in whom a CR or PR is observed as best overall response; according to RECIST 1.1
Objective Response Rate (ORR)
[ Time Frame: up to 2 Years ]

ORR defined as the proportion of patients in whom a CR or PR is observed as best overall response; according to RECIST 1.1
4. Disease Control Rate (DCR)
[ Time Frame: up to 2 Years ]

DCR defined as the proportion of patients in whom a CR or PR or SD (assessed at least 6 weeks after first dose) is observed as best overall response; according to RECIST 1.1
Disease Control Rate (DCR)
[ Time Frame: up to 2 Years ]

DCR defined as the proportion of patients in whom a CR or PR or SD (assessed at least 6 weeks after first dose) is observed as best overall response; according to RECIST 1.1
5. Duration of Response (DOR)
[ Time Frame: up to 2 Years ]

DOR defined as the time from first objective response (CR or PR) to the date of the first occurrence of objective tumor progression (PD); according to RECIST 1.1
Duration of Response (DOR)
[ Time Frame: up to 2 Years ]

DOR defined as the time from first objective response (CR or PR) to the date of the first occurrence of objective tumor progression (PD); according to RECIST 1.1
Other Outcome Measures:
1. immune Objective Response Rate (iORR)
[ Time Frame: up to 2 Years ]

iORR defined as the proportion of patients in whom a iCR or iPR is observed as best overall response.

iDCR defined as the proportion of patients in whom a iCR or iPR or iSD (assessed at least 6 weeks after first dose) is observed as best overall response; according to iRECIST

immune Objective Response Rate (iORR)
[ Time Frame: up to 2 Years ]

iORR defined as the proportion of patients in whom a iCR or iPR is observed as best overall response.

iDCR defined as the proportion of patients in whom a iCR or iPR or iSD (assessed at least 6 weeks after first dose) is observed as best overall response; according to iRECIST

2. immune Disease Control Rate (iDCR)
[ Time Frame: up to 2 Years ]

iDCR defined as the proportion of patients in whom a iCR or iPR or iSD (assessed at least 6 weeks after first dose) is observed as best overall response; according to iRECIST
immune Disease Control Rate (iDCR)
[ Time Frame: up to 2 Years ]

iDCR defined as the proportion of patients in whom a iCR or iPR or iSD (assessed at least 6 weeks after first dose) is observed as best overall response; according to iRECIST
3. immune Duration of Response (iDOR)
[ Time Frame: up to 2 Years ]

iDOR defined as the time from first objective response (iCR or iPR) to the date of the first occurrence of objective tumour progression (iCPD); according to iRECIST
immune Duration of Response (iDOR)
[ Time Frame: up to 2 Years ]

iDOR defined as the time from first objective response (iCR or iPR) to the date of the first occurrence of objective tumour progression (iCPD); according to iRECIST
4. Progression Free Survival (PFS) time
[ Time Frame: up to 3 Years ]

PFS defined as the time from first dose of IMP to first occurrence of objective tumor progression (per RECIST 1.1), or death from any cause, whichever occurs first
Progression Free Survival (PFS) time
[ Time Frame: up to 3 Years ]

PFS defined as the time from first dose of IMP to first occurrence of objective tumor progression (per RECIST 1.1), or death from any cause, whichever occurs first
5. Overall Survival (OS) time
[ Time Frame: up to 3 Years ]

OS defined as the time from first dose of IMP to death from any cause
Overall Survival (OS) time
[ Time Frame: up to 3 Years ]

OS defined as the time from first dose of IMP to death from any cause
Open or close this module Eligibility
Minimum Age: 18 Years 18 Years
Maximum Age:
Sex: All All
Gender Based:
Accepts Healthy Volunteers: NoNo
Criteria:

Inclusion Criteria:

For Part 1A:

  • Histologically confirmed solid tumor (cytology is allowed for NSCLC, SCLC and pancreatic cancer) that is metastatic or unresectable and for which there is no available standard therapy likely to confer clinical benefit, or patients who are not candidates for such available therapy.

For Part 1B:

  • Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system) who received no prior chemotherapy for extensive stage disease.
  • Those treated with prior chemo/radiotherapy with curative intent for LS-SCLC should be treatment-free for at least 6 months since last chemo/radiotherapy.
  • Has no interstitial lung disease or active, non-infectious pneumonitis.

For Both Part 1A and Part 1B

  • Male and female ≥ 18 years of age.
  • Must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the trial and are willing to participate in the trial prior to any trial related assessments or procedures.
  • ECOG performance status of 0 to 1.
  • Measurable disease according to RECIST 1.1.
  • Albumin level at screening ≥30 g/L.
  • Able to receive the first administration of trial treatment within 42 days from the last documented disease progression.
  • Adequate coagulation function at Screening as determined by:
    1. International normalized ratio (INR) or prothrombin time ≤1.5 x upper limit normal (ULN; unless on therapeutic anticoagulants with values within therapeutic window),
    2. Activated partial thromboplastin time (aPTT) ≤1.5 x ULN (unless on therapeutic anticoagulants with values within therapeutic window).
  • Adequate hematologic function at Screening as determined by:
    1. White blood count (WBC) ≥3 x 10^9/L
    2. Absolute neutrophil count (ANC) ≥1.5 x 10^9/L (patient may not use granulocyte-colony stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF) to achieve these WBC and ANC levels),
    3. Platelet count ≥100 x 10^9/L,
    4. Hemoglobin (Hgb) ≥9.0 g/dL (may not transfuse or use erythropoietin to obtain this Hgb level).
  • Adequate hepatic function at Screening as determined by:
    1. Total bilirubin ≤ 1.5 mg/dL (or ≤ 2.0 mg/dL for patients with known Gilbert's syndrome),
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN; or ≤5 x ULN in patients with metastatic liver disease.
  • Adequate renal function at Screening as determined by:

    a. Glomerular filtration rate (GFR) ≥60 mL/min/1.73 m²- e.g., according to the abbreviated Modification of Diet in Renal Disease (MDRD) equation: GFR = 186 × (SCr-1.154) × (age-0.203) (where SCr, the serum creatinine level, is expressed in mg/dL; multiplied by 0.742 if the patient is female; multiplied by 1.212, if the patient is African-American (Levey et al., 1999).

  • Able to attend trial visits as required by the protocol.
  • Women of childbearing potential (WOCBP) must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) test/value at Screening. Patients who are postmenopausal or permanently sterilized can be considered as not having reproductive potential.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial, until 6 months after last BNT411 treatment.
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the trial and for 6 months after receiving the last dose of BNT411.
  • All patients must provide an FFPE (Formalin Fixed Paraffin Embedded) from the latest available archival tumor tissue. If such tissue cannot be provided, the sponsor's approval of enrollment is needed.

Exclusion Criteria:

Prior and Concomitant Therapy:

  • Has received prior systemic therapy with a TLR7 agonist.
  • Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors within 2 weeks or 5 half-lives (whichever is longer) of the start of trial treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of trial treatment; any live vaccine within 4 weeks of the start of trial treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of trial treatment.
  • Receives concurrent systemic (oral or intravenous) steroid therapy >10 mg prednisone daily or its equivalent for an underlying condition.
  • Receives concurrent strong inhibitors or inducers of the cytochrome P450 enzymes.
  • Has had major surgery within the 4 weeks before the first dose of BNT411.
  • Has ongoing or active infection requiring intravenous treatment with anti-infective therapy that has been administered less than two weeks prior to first dose of trial treatment.
  • Has side effects of any prior therapy or procedures for any medical condition not recovered to NCI CTCAE v.5 grade ≤1.
  • Has any contraindication to atezolizumab, carboplatin or etoposide as per USPI or SmPC in Part 1B.

Medical Conditions

  • Current evidence of new or growing brain or leptomeningeal metastases during screening. Patients with known brain or leptomeningeal metastases may be eligible if they:
    1. had radiotherapy, surgery or stereotactic surgery for the brain or leptomeningeal metastases,
    2. have no neurological symptoms (excluding Grade ≤2 neuropathy),
    3. have stable brain or leptomeningeal disease on the CT or MRI scan within 4 weeks before signing the informed consent,
    4. are not undergoing acute corticosteroid therapy or steroid taper.
  • Has history of seizures other than isolated febrile seizure in childhood; has a history of a cerebrovascular accident or transient ischemic attack less than 6 months ago.
  • Has effusions (pleural, pericardial, or ascites) requiring drainage.
  • Has eye pathology likely to confound observation of potential ocular AEs.
  • Has a fever ≥38°C within 3 days before signing the ICF.
  • Has a history of autoimmune disease active or past including but not limited to inflammatory bowel disease, systemic lupus erythematosus (SLE), ankylosing spondylitis, scleroderma, or multiple sclerosis. Has any active immunologic disorder requiring immunosuppression with steroids or other immunosuppressive agents (e.g., azathioprine, cyclosporine A) with the exception of patients with isolated vitiligo, resolved childhood asthma or atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and euthyroid patients with a history of Grave's disease. Patients with controlled hyperthyroidism must be negative for thyroglobulin, thyroid peroxidase antibodies, and thyroid-stimulating immunoglobulin prior to trial drug administration.
  • Known history of seropositivity for human immunodeficiency virus (HIV) with CD4+ T-cell (CD4+) counts <350 cells/uL and with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.
  • Known history/positive serology for hepatitis B requiring active anti-viral therapy (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy). Patients with positive serology must have Hepatitis B virus (HBV) viral load below the limit of quantification.
  • Active Hepatitis C virus (HCV) infection; patients who have completed curative antiviral treatment with HCV viral load below the limit of quantification are allowed.
  • Has a known hypersensitivity to a component of BNT411 drug product, or another similar compound.
  • Has another primary malignancy that has not been in remission for at least 2 years, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ).

Other Comorbidities

  • Has abnormal electrocardiograms (ECGs) that are clinically significant, such as Framingham-corrected QT interval >480 ms.
  • In the opinion of the treating investigator, has any concurrent conditions that could pose an undue medical hazard or interfere with the interpretation of the trial results; these conditions include, but are not limited to:
    1. ongoing or active infection requiring antibiotic/antiviral/antifungal therapy,
    2. concurrent congestive heart failure (New York Heart Association [NYHA] Functional Classification Class III or IV),
    3. concurrent unstable angina,
    4. concurrent cardiac arrhythmia requiring treatment (excluding asymptomatic atrial fibrillation),
    5. acute coronary syndrome within the previous 6 months,
    6. significant pulmonary disease (shortness of breath at rest or on mild exertion) for example due concurrent severe obstructive pulmonary disease.
  • Has a cognitive, psychological or psychosocial impediment that would impair the ability of the patient to receive therapy according to the protocol or adversely affect the ability of the patient to comply with the informed consent process, protocol, or protocol-required visits and procedures.
  • Is pregnant or breastfeeding.

Inclusion Criteria:

For Part 1A:

  • Histologically confirmed solid tumor (cytology is allowed for NSCLC, SCLC and pancreatic cancer) that is metastatic or unresectable and for which there is no available standard therapy likely to confer clinical benefit, or patients who are not candidates for such available therapy.

For Part 1B:

  • Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system) who received no prior chemotherapy for extensive stage disease.
  • Those treated with prior chemo/radiotherapy with curative intent for LS-SCLC should be treatment-free for at least 6 months since last chemo/radiotherapy.
  • Has no interstitial lung disease or active, non-infectious pneumonitis.

For Both Part 1A and Part 1B

  • Male and female ≥ 18 years of age.
  • Must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the trial and are willing to participate in the trial prior to any trial related assessments or procedures.
  • ECOG performance status of 0 to 1.
  • Measurable disease according to RECIST 1.1.
  • Albumin level at screening ≥30 g/L.
  • Able to receive the first administration of trial treatment within 42 days from the last documented disease progression.
  • Adequate coagulation function at Screening as determined by:
    1. International normalized ratio (INR) or prothrombin time ≤1.5 x upper limit normal (ULN; unless on therapeutic anticoagulants with values within therapeutic window),
    2. Activated partial thromboplastin time (aPTT) ≤1.5 x ULN (unless on therapeutic anticoagulants with values within therapeutic window).
  • Adequate hematologic function at Screening as determined by:
    1. White blood count (WBC) ≥3 x 10^9/L
    2. Absolute neutrophil count (ANC) ≥1.5 x 10^9/L (patient may not use granulocyte-colony stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF) to achieve these WBC and ANC levels),
    3. Platelet count ≥100 x 10^9/L,
    4. Hemoglobin (Hgb) ≥9.0 g/dL (may not transfuse or use erythropoietin to obtain this Hgb level).
  • Adequate hepatic function at Screening as determined by:
    1. Total bilirubin ≤ 1.5 mg/dL (or ≤ 2.0 mg/dL for patients with known Gilbert's syndrome),
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN; or ≤5 x ULN in patients with metastatic liver disease.
  • Adequate renal function at Screening as determined by:

    a. Glomerular filtration rate (GFR) ≥60 mL/min/1.73 m²- e.g., according to the abbreviated Modification of Diet in Renal Disease (MDRD) equation: GFR = 186 × (SCr-1.154) × (age-0.203) (where SCr, the serum creatinine level, is expressed in mg/dL; multiplied by 0.742 if the patient is female; multiplied by 1.212, if the patient is African-American (Levey et al., 1999).

  • Able to attend trial visits as required by the protocol.
  • Women of childbearing potential (WOCBP) must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) test/value at Screening. Patients who are postmenopausal or permanently sterilized can be considered as not having reproductive potential.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial, until 6 months after last BNT411 treatment.
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the trial and for 6 months after receiving the last dose of BNT411.
  • All patients must provide an FFPE (Formalin Fixed Paraffin Embedded) from the latest available archival tumor tissue. If such tissue cannot be provided, the sponsor's approval of enrollment is needed.

Exclusion Criteria:

Prior and Concomitant Therapy:

  • Has received prior systemic therapy with a TLR7 agonist.
  • Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors within 2 weeks or 5 half-lives (whichever is longer) of the start of trial treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of trial treatment; any live vaccine within 4 weeks of the start of trial treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of trial treatment.
  • Receives concurrent systemic (oral or intravenous) steroid therapy >10 mg prednisone daily or its equivalent for an underlying condition.
  • Receives concurrent strong inhibitors or inducers of the cytochrome P450 enzymes.
  • Has had major surgery within the 4 weeks before the first dose of BNT411.
  • Has ongoing or active infection requiring intravenous treatment with anti-infective therapy that has been administered less than two weeks prior to first dose of trial treatment.
  • Has side effects of any prior therapy or procedures for any medical condition not recovered to NCI CTCAE v.5 grade ≤1.
  • Has any contraindication to atezolizumab, carboplatin or etoposide as per USPI or SmPC in Part 1B.

Medical Conditions

  • Current evidence of new or growing brain or leptomeningeal metastases during screening. Patients with known brain or leptomeningeal metastases may be eligible if they:
    1. had radiotherapy, surgery or stereotactic surgery for the brain or leptomeningeal metastases,
    2. have no neurological symptoms (excluding Grade ≤2 neuropathy),
    3. have stable brain or leptomeningeal disease on the CT or MRI scan within 4 weeks before signing the informed consent,
    4. are not undergoing acute corticosteroid therapy or steroid taper.
  • Has history of seizures other than isolated febrile seizure in childhood; has a history of a cerebrovascular accident or transient ischemic attack less than 6 months ago.
  • Has effusions (pleural, pericardial, or ascites) requiring drainage.
  • Has eye pathology likely to confound observation of potential ocular AEs.
  • Has a fever ≥38°C within 3 days before signing the ICF.
  • Has a history of autoimmune disease active or past including but not limited to inflammatory bowel disease, systemic lupus erythematosus (SLE), ankylosing spondylitis, scleroderma, or multiple sclerosis. Has any active immunologic disorder requiring immunosuppression with steroids or other immunosuppressive agents (e.g., azathioprine, cyclosporine A) with the exception of patients with isolated vitiligo, resolved childhood asthma or atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and euthyroid patients with a history of Grave's disease. Patients with controlled hyperthyroidism must be negative for thyroglobulin, thyroid peroxidase antibodies, and thyroid-stimulating immunoglobulin prior to trial drug administration.
  • Known history of seropositivity for human immunodeficiency virus (HIV) with CD4+ T-cell (CD4+) counts <350 cells/uL and with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.
  • Known history/positive serology for hepatitis B requiring active anti-viral therapy (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy). Patients with positive serology must have Hepatitis B virus (HBV) viral load below the limit of quantification.
  • Active Hepatitis C virus (HCV) infection; patients who have completed curative antiviral treatment with HCV viral load below the limit of quantification are allowed.
  • Has a known hypersensitivity to a component of BNT411 drug product, or another similar compound.
  • Has another primary malignancy that has not been in remission for at least 2 years, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ).

Other Comorbidities

  • Has abnormal electrocardiograms (ECGs) that are clinically significant, such as Framingham-corrected QT interval >480 ms.
  • In the opinion of the treating investigator, has any concurrent conditions that could pose an undue medical hazard or interfere with the interpretation of the trial results; these conditions include, but are not limited to:
    1. ongoing or active infection requiring antibiotic/antiviral/antifungal therapy,
    2. concurrent congestive heart failure (New York Heart Association [NYHA] Functional Classification Class III or IV),
    3. concurrent unstable angina,
    4. concurrent cardiac arrhythmia requiring treatment (excluding asymptomatic atrial fibrillation),
    5. acute coronary syndrome within the previous 6 months,
    6. significant pulmonary disease (shortness of breath at rest or on mild exertion) for example due concurrent severe obstructive pulmonary disease.
  • Has a cognitive, psychological or psychosocial impediment that would impair the ability of the patient to receive therapy according to the protocol or adversely affect the ability of the patient to comply with the informed consent process, protocol, or protocol-required visits and procedures.
  • Is pregnant or breastfeeding.
Open or close this module Contacts/Locations
Central Contact Person: BioNTech clinical trials patient information
Telephone: +49 6131 9084 Ext. 0
Email: patients@biontech.de
BioNTech clinical trials patient information
Telephone: +49 6131 9084 Ext. 0
Email: patients@biontech.de
Study Officials: BioNTech Responsible Person
Study Director
BioNTech SE
BioNTech Responsible Person
Study Director
BioNTech SE
Locations: United States, CaliforniaUnited States, California
Cedars-Sinai Medical Center
[Recruiting]
Los Angeles, California, United States, 90048
Cedars-Sinai Medical Center
[Recruiting]
Los Angeles, California, United States, 90048
United States, IllinoisUnited States, Illinois
Northwestern Medical Faculty Foundation
[Recruiting]
Chicago, Illinois, United States, 60611
Northwestern Medical Faculty Foundation
[Recruiting]
Chicago, Illinois, United States, 60611
United States, South CarolinaUnited States, South Carolina
Prisma Health-Upstate Cancer Institute
[Not yet recruiting]
Greenville, South Carolina, United States, 29605
Prisma Health-Upstate Cancer Institute
[Not yet recruiting]
Greenville, South Carolina, United States, 29605
GermanyGermany
University Medical Center Hamburg-Eppendorf
[Not yet recruiting]
Hamburg, Germany, 20246
University Medical Center Hamburg-Eppendorf
[Not yet recruiting]
Hamburg, Germany, 20246
Universitaetsklinikum Koeln
[Active, not recruiting]
Koeln, Germany, 50937
Universitaetsklinikum Koeln
[Active, not recruiting]
Koeln, Germany, 50937
Universitaetsmedizin der Johannes Gutenberg Universitat Mainz KoeR - (Recruiting only for part 1B and part 2)
[Active, not recruiting]
Mainz, Germany, 55131
Universitaetsmedizin der Johannes Gutenberg Universitat Mainz KoeR - (Recruiting only for part 1B and part 2)
[Active, not recruiting]
Mainz, Germany, 55131
SpainSpain
Hospital Universitari Vall d'Hebron
[Recruiting]
Barcelona, Spain, 08035
Hospital Universitari Vall d'Hebron
[Recruiting]
Barcelona, Spain, 08035
Clinica Universidad de Navarra
[Recruiting]
Madrid, Spain, 28022
Clinica Universidad de Navarra
[Recruiting]
Madrid, Spain, 28022
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC)
[Recruiting]
Madrid, Spain, 28050
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC)
[Recruiting]
Madrid, Spain, 28050
Hospital Universitario La Fe de Valencia
[Recruiting]
Valencia, Spain, 46026
Hospital Universitario La Fe de Valencia
[Recruiting]
Valencia, Spain, 46026
United KingdomUnited Kingdom
Edinburgh Cancer Research Centre
[Recruiting]
Edinburgh, United Kingdom, EH4 2XU
Edinburgh Cancer Research Centre
[Recruiting]
Edinburgh, United Kingdom, EH4 2XU
Sarah Cannon Research Institute
[Recruiting]
London, United Kingdom, W1G 6AD
Sarah Cannon Research Institute
[Recruiting]
London, United Kingdom, W1G 6AD
Open or close this module IPDSharing
Plan to Share IPD: No No
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services